Showing results (51-60 of 61) with videos related to
Sort By:
Pageof 7
Lung Cancer (Amsterdam, Netherlands)|March 18, 2025
Pathological & radiological variables in the diagnosis of bronchopulmonary carcinoids (BPCs) with a focus on Antigen Kiel 67 (Ki-67) proliferation indexGaurav Ahuja, Aparna Iyer, Rachel Harwood, et al.The Lancet. Oncology|October 28, 2017
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trialPiero Ferolla, Maria Pia Brizzi, Tim Meyer, et al.The Lancet. Oncology|June 22, 2014
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trialSusan J Dutton, David R Ferry, Jane M Blazeby, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2017
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal CancerRussell D Petty, Asa Dahle-Smith, David A J Stevenson, et al.Eclinicalmedicine|June 8, 2023
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinomaMairéad G McNamara, Jayne Swain, Zoe Craig, et al.Lancet (London, England)|August 29, 2021
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 studyJong-Mu Sun, Lin Shen, Manish A Shah, et al.The New England Journal of Medicine|June 2, 2025
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric CancerKohei Shitara, Eric Van Cutsem, Mahmut Gümüş, et al.The Lancet. Oncology|February 6, 2019
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialCharles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, et al.JAMA Oncology|September 4, 2020
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical TrialKohei Shitara, Eric Van Cutsem, Yung-Jue Bang, et al.The New England Journal of Medicine|February 2, 2022
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell CarcinomaYuichiro Doki, Jaffer A Ajani, Ken Kato, et al.Pageof 7